Role of Angiotensin II in the Evolution of Diastolic Heart Failure

No abstract is available for this paper.

• Publication year

  2005

• Venue

  The Journal of Clinical Hypertension

• Publication date

  2005-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1524-6175.2005.04889.xPMID 16330897PMCID PMC8109311
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy

  2005cited by this paper
• Outcomes and prognostic factors of systolic as compared with diastolic heart failure in urban America.

  2005cited by this paper
• The natriuretic peptides

  2004cited by this paper
• A practical approach to the echocardiographic evaluation of diastolic function.

  2004cited by this paper
• Heart failure: how important is cellular sequestration? The role of the renin-angiotensin-aldosterone system.

  2004cited by this paper
• Management of diastolic heart failure.

  2004cited by this paper
• Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle.

  2004cited by this paper
• Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy.

  2004cited by this paper
• Renal Insufficiency and Heart Failure: Prognostic and Therapeutic Implications From a Prospective Cohort Study

  2004cited by this paper
• Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey.

  2004cited by this paper
• Heart failure: how important is cellular sequestration? The role of the renin-angiotensin-aldosterone system.

  2004cited by this paper
• Heart failure/transplant: abstractEffects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT)☆

  2003cited by this paper
• Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure—Assessment of Reduction in Mortality and morbidity (CHARM) programme

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

  2003cited by this paper
• Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study.

  2003cited by this paper
• Sustained Reduction of Aldosterone in Response to the Angiotensin Receptor Blocker Valsartan in Patients With Chronic Heart Failure: Results From the Valsartan Heart Failure Trial

  2003cited by this paper
• Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study

  2003cited by this paper
• Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic.

  2003cited by this paper
• A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.

  2003cited by this paper
• Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT)

  2002cited by this paper
• Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study.

  2002cited by this paper
• Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women.

  2002cited by this paper
• Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent Effect

  2002cited by this paper
• New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment.

  2002cited by this paper
• Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.

  2002cited by this paper
• Cardiorenal risk: an important clinical intersection.

  2002cited by this paper
• Treatment of Congestive Heart Failure: Interfering the Aldosterone-Cardiac Extracellular Matrix Relationship

  2001cited by this paper
• Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study.

  2001cited by this paper
• Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril

  2001cited by this paper
• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

  2001cited by this paper
• Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension.

  2001cited by this paper
• Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures: A HOPE Substudy

  2001cited by this paper
• Heart Failure With a Normal Ejection Fraction: Is Measurement of Diastolic Function Necessary to Make the Diagnosis of Diastolic Heart Failure?

  2001cited by this paper
• The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

  2001cited by this paper
• Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.

  2001cited by this paper
• Diastolic heart failure--no time to relax.

  2001cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• Importance of heart failure with preserved systolic function in patients ≥65 years of age

  2001cited by this paper
• Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril

  2001cited by this paper
• Defining diastolic heart failure: a call for standardized diagnostic criteria.

  2000cited by this paper
• Chronic AT(1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats.

  2000cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

  2000cited by this paper
• Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.

  2000cited by this paper
• Chronic AT1 Blockade Stimulates Extracellular Collagen Type I Degradation and Reverses Myocardial Fibrosis in Spontaneously Hypertensive Rats

  2000cited by this paper
• Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.

  2000cited by this paper
• Diastolic heart failure.

  2000cited by this paper
• Local neurohumoral regulation in the transition to isolated diastolic heart failure in hypertensive heart disease: absence of AT1 receptor downregulation and 'overdrive' of the endothelin system.

  2000cited by this paper
• Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study.

  2000cited by this paper
• How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?

  1999cited by this paper
• Hormones and hemodynamics in heart failure.

  1999cited by this paper
• Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort.

  1999cited by this paper
• Profile for estimating risk of heart failure.

  1999cited by this paper
• Effects of valsartan on left ventricular diastolic function in patients with mild or moderate essential hypertension: comparison with enalapril.

  1999cited by this paper
• Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.

  1999cited by this paper
• Natriuretic peptides.

  1998cited by this paper
• Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991.

  1998cited by this paper
• Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease.

  1997cited by this paper
• The epidemiology of heart failure.

  1997cited by this paper
• ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure.

  1997cited by this paper
• Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts

  1996cited by this paper
• Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective.

  1995cited by this paper
• Angiotensin II induces TIMP-1 production in rat heart endothelial cells.

  1994cited by this paper
• Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction.

  1994cited by this paper
• Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension.

  1993cited by this paper
• Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system.

  1992cited by this paper
• Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies.

  1992cited by this paper
• Heart failure with normal ejection fraction. The V-HeFT study

  1990cited by this paper
• Heart failure with normal ejection fraction. The V-HeFT Study. Veterans Administration Cooperative Study Group.

  1990cited by this paper
• Usefulness of Doppler echocardiography in the diagnosis of congestive heart failure.

  1989cited by this paper
• Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats.

  1989cited by this paper
• Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension.

  1984cited by this paper
• Direct myocardial effects of angiotensin II.

  1971cited by this paper
• Treatment of Congestive Heart Failure Interfering the Aldosterone-cardiac Extracellular Matrix Relationship

  year unknowncited by this paper

• Liraglutide protects against diastolic dysfunction and improves ventricular protein translation

  2023cites this paper
• Negative Effects of Chronic High Intake of Fructose on Lung Diseases

  2022cites this paper
• Novel Biomarkers of Chronic Cardiorenal Disease

  2020cites this paper
• Gene expression profiling of hypertrophic cardiomyocytes identifies new players in pathological remodelling

  2020cites this paper
• Sex and Heart Failure with Preserved Ejection Fraction: From Pathophysiology to Clinical Studies

  2019cites this paper
• Cardiovascular renal axis disorder and inflammatory response in feline congestive heart failure due to primary cardiomyopathy

  2019cites this paper
• Cardio-Renal Syndrome Type 1: The Role of Central Venous Pressure and Left Ventricle Ejection Fraction

  2017cites this paper
• Perioperative management of left ventricular diastolic dysfunction and heart failure: an anesthesiologist's perspective

  2017cites this paper
• High‐intensity interval training has beneficial effects on cardiac remodeling through local renin‐angiotensin system modulation in mice fed high‐fat or high‐fructose diets

  2017cites this paper
• Dipeptidyl Peptidase‐4 Inhibition With Saxagliptin Ameliorates Angiotensin II‐Induced Cardiac Diastolic Dysfunction in Male Mice

  2017cites this paper
• The role of right-sided heart failure in patients with Cardio-Renal Syndrome

  2016cites this paper
• Aldosterone-induced cardiomyocyte growth, and fibroblast migration and proliferation are mediated by TRAF3IP2.

  2015cites this paper
• Angiotensin Ⅱ Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4.

  2015cites this paper
• Herzinsuffizienz mit erhaltener LV-Funktion

  2014cites this paper
• Heart failure with normal ejection fraction: current diagnostic and management strategies

  2013cites this paper
• Inadequate RAAS suppression is associated with excessive left ventricular mass and systo-diastolic dysfunction

  2013cites this paper
• Type 4 Cardiorenal Syndrome: Myocardial Dysfunction, Fibrosis, and Heart Failure in Patients with Chronic Kidney Disease

  2012cites this paper
• Cardiorenal syndromes.

  2011cites this paper
• Micronutrients and Cardiorenal Disease: Insights into Novel Assessments and Treatment

  2011cites this paper
• Safety and efficacy of rennin-angiotensin system inhibitors in heart failure with preserved ejection fraction

  2011cites this paper
• Influence of myocardial ischemia on outcomes in patients with systolic versus non-systolic heart failure.

  2011cites this paper
• Renin‐Angiotensin‐Aldosterone System in Diabetes and Hypertension

  2011cites this paper
• Original Article Influence of myocardial ischemia on outcomes in patients with systolic versus non-systolic heart failure

  2011cites this paper
• Galectin-3: a novel blood test for the evaluation and management of patients with heart failure.

  2011cites this paper
• Cuál es el rol del sistema neurohormonal en la insuficiencia cardíaca con fracción de eyección preservada

  2010cites this paper
• Cardiorenal Syndromes: Pathophysiology to Prevention

  2010cites this paper
• The challenges associated with current clinical trials for diastolic heart failure

  2009cites this paper
• A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction

  2009cites this paper
• Postanesthesia Care of the Obese Patient

  2009cites this paper
• Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction.

  2009cites this paper
• PRL PTPs: mediators and markers of cancer progression

  2008cites this paper
• Chapter 27 – Role of Neurohormones

  2008cites this paper
• General Treatment of Diastolic Heart Failure

  2008cites this paper
• Optimal treatment of hypertension with diastolic heart failure.

  2008cites this paper
• Influence of chronic renal insufficiency on left ventricular diastolic function in hypertensives without left ventricular hypertrophy.

  2007cites this paper
• Diastolic heart failure in anaesthesia and critical care.

  2007cites this paper
• Curriculum in cardiology: integrated diagnosis and management of diastolic heart failure.

  2007cites this paper
• REVIEWARTICLE Diastolic heart failure in anaesthesia and critical care

  2007cites this paper